Lenalidomide, Sunitinib, and Cyclophosphamide in Treating Patients With Stage IV Eye Melanoma
Status:
Terminated
Trial end date:
2009-04-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Lenalidomide may stop the growth of tumor cells by blocking blood flow to the
tumor. Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed
for cell growth. Drugs used in chemotherapy, such as cyclophosphamide, work in different ways
to stop the growth of tumor cells, either by killing the cells or by stopping them from
dividing. Giving lenalidomide together with sunitinib and low doses of cyclophosphamide once
a day may kill more tumor cells.
PURPOSE: This phase II trial is studying how well giving lenalidomide together with sunitinib
and cyclophosphamide works in treating patients with stage IV eye melanoma.
Phase:
Phase 2
Details
Lead Sponsor:
National Institutes of Health Clinical Center (CC)